Icecure Medical is trading 7.41% up at $1.16 in pre-market on October 13, 2026, with no clear company-specific catalyst identified.
- The latest company announcement found was an October 6 update adding a clinical site to its ChoICE study.
- Healthcare-sector strength may be supportive, with managed-care shares rising on rating news and earnings optimism; available reports do not establish a direct link to Icecure Medical’s gain.